NCT00167219 · OUTCOME

Determine Probability of Long-term Disease Free Survival in JMML

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) · Source last updated 2023-11-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: at 1 year after transplant

Groups in this outcome

Intent-to-Treat

Patients receiving study regimen. Stem Cell Transplant: Transplantation on Day 0. Preparative Regimen: - Busulfan * Cyclophosphamide * Mesna * Melphalan * Anti-thymocyte Globulin (ATG)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Intent-to-Treat	15

Reported measurements

Source class 1

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Intent-to-Treat	67	Not reported	38	85	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
38
upper Limit
85
value
67

denoms

counts
group Id
OG000
value
15
units
Participants

dispersion Type

95% Confidence Interval

groups

description
Patients receiving study regimen. Stem Cell Transplant: Transplantation on Day 0. Preparative Regimen: - Busulfan * Cyclophosphamide * Mesna * Melphalan * Anti-thymocyte Globulin (ATG)
id
OG000
title
Intent-to-Treat

param Type

NUMBER

reporting Status

POSTED

time Frame

at 1 year after transplant

title

Determine Probability of Long-term Disease Free Survival in JMML

type

PRIMARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice